DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced today that Todd Cooper, President and CEO, is scheduled to present at the JMP Securities Life Sciences Conference 2016 on Tuesday, June 21 at 3:00 p.m. ET. The Conference is being held June 21 and 22, 2016 at The St. Regis New York.
Presbia has developed and is marketing the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia. Mr. Cooper will discuss Presbia’s current international commercial strategy, with a focus in South Korea, one of the largest ophthalmology markets in the world. South Korea has one of the highest per capita incidences of presbyopia, the age-related loss of near-vision, and is also one of the most penetrated markets for LASIK surgery. The combination of both of these factors makes South Korea an ideal market for the Company to launch its innovative solution for presbyopia. Mr. Cooper will also discuss a peer-to-peer surgeon symposium that is being held in Seoul, South Korea this month. It will be attended by approximately 20 eminent South Korean surgeons who have expressed strong interest in the Presbia Microlens solution for near sightedness.
Mr. Cooper will be available for one-on-one meetings at the Conference.
Forward-Looking Statements
Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
About Presbia
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.
